UiPath (NYSE:PATH) Stock Price Up 1.2%

Shares of UiPath Inc. (NYSE:PATH) traded up 1.2% during trading on Monday . The stock traded as high as $19.90 and last traded at $19.72. 1,466,209 shares were traded during trading, a decline of 83% from the average session volume of 8,384,261 shares. The stock had previously closed at $19.48.

Analysts Set New Price Targets

Several analysts have issued reports on PATH shares. Barclays upped their price target on shares of UiPath from $23.00 to $25.00 and gave the company an “equal weight” rating in a research report on Friday, March 15th. JPMorgan Chase & Co. raised shares of UiPath from a “neutral” rating to an “overweight” rating and increased their price target for the company from $22.00 to $28.00 in a research report on Thursday, March 14th. Canaccord Genuity Group boosted their price objective on shares of UiPath from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, March 15th. Needham & Company LLC reiterated a “buy” rating and set a $30.00 target price on shares of UiPath in a report on Wednesday, March 20th. Finally, Scotiabank raised their target price on UiPath from $29.00 to $30.00 and gave the stock a “sector perform” rating in a research note on Thursday, March 14th. Nine research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, UiPath has a consensus rating of “Moderate Buy” and a consensus price target of $27.41.

UiPath Stock Performance

The stock has a market capitalization of $11.29 billion, a P/E ratio of -116.40 and a beta of 1.01. The business has a 50-day moving average price of $21.75 and a 200 day moving average price of $21.72.

UiPath (NYSE:PATH) last released its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The business had revenue of $405.25 million for the quarter, compared to the consensus estimate of $383.32 million. As a group, research analysts forecast that UiPath Inc. will post -0.04 earnings per share for the current fiscal year.

Insider Activity at UiPath

In related news, CFO Ashim Gupta sold 16,000 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $22.84, for a total transaction of $365,440.00. Following the completion of the sale, the chief financial officer now owns 87,505 shares of the company’s stock, valued at $1,998,614.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 31.03% of the stock is currently owned by insiders.

Institutional Investors Weigh In On UiPath

Several institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP boosted its stake in shares of UiPath by 150.3% in the 1st quarter. GSA Capital Partners LLP now owns 26,054 shares of the healthcare company’s stock worth $591,000 after buying an additional 15,644 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S grew its stake in shares of UiPath by 10,718.8% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 42,518 shares of the healthcare company’s stock valued at $964,000 after purchasing an additional 42,125 shares during the period. Daiwa Securities Group Inc. increased its position in shares of UiPath by 5.4% during the 1st quarter. Daiwa Securities Group Inc. now owns 25,400 shares of the healthcare company’s stock valued at $576,000 after purchasing an additional 1,300 shares during the last quarter. Greenwood Capital Associates LLC purchased a new position in shares of UiPath in the first quarter worth approximately $235,000. Finally, Janney Montgomery Scott LLC grew its position in UiPath by 27.2% during the first quarter. Janney Montgomery Scott LLC now owns 89,340 shares of the healthcare company’s stock valued at $2,025,000 after buying an additional 19,126 shares during the period. 62.50% of the stock is owned by hedge funds and other institutional investors.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.